4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD DME and 4D-710 in CF and Extends ...
FDMT Stock | USD 4.48 0.32 6.67% |
Slightly above 67% of 4D Molecular's investor base is looking to short. The analysis of the overall investor sentiment regarding 4D Molecular Therapeutics suggests that many traders are alarmed. 4D Molecular's investing sentiment can be driven by a variety of factors including economic data, 4D Molecular's earnings reports, geopolitical events, and overall market trends.
FDMT |
Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept 4D-150 for wet AMD and
Read at gurufocus.com
![]() |
4D Molecular Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards 4D Molecular can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
4D Molecular Fundamental Analysis
We analyze 4D Molecular's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 4D Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 4D Molecular based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
4D Molecular is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
4D Molecular Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 4D Molecular stock to make a market-neutral strategy. Peer analysis of 4D Molecular could also be used in its relative valuation, which is a method of valuing 4D Molecular by comparing valuation metrics with similar companies.
Peers
4D Molecular Related Equities
EWTX | Edgewise Therapeutics | 3.21 | ||||
MLYS | Mineralys Therapeutics, | 2.89 | ||||
CGEM | Cullinan Oncology | 1.89 | ||||
AKRO | Akero Therapeutics | 0.34 | ||||
NVCT | Nuvectis Pharma | 1.01 | ||||
BMEA | Biomea Fusion | 1.41 | ||||
CCCC | C4 Therapeutics | 1.89 | ||||
KRON | Kronos Bio | 2.04 | ||||
IPSC | Century Therapeutics | 2.90 | ||||
STOK | Stoke Therapeutics | 3.39 | ||||
RVMD | Revolution Medicines | 3.51 | ||||
PASG | Passage Bio | 3.77 | ||||
REPL | Replimune | 4.53 | ||||
LYRA | Lyra Therapeutics | 4.76 | ||||
BDTX | Black Diamond | 5.37 | ||||
GOSS | Gossamer Bio | 8.46 |
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.